Aciclovir

25mg/mL injection, 200mg tablet

Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms
acyclovir, acycloguanosin

Dose and Indications

Varicella zoster virus (VZV) infection; treatment

- Neonates presenting with chickenpox who are unwell (e.g. poor feeding, tachypnoea) whether or not they received Varicella Zoster Immune Globulin (VZIG)
- Any immunocompromised neonate who develops chickenpox, including those who are premature (less than 37 weeks) or being treated with corticosteroids, whether or not they received VZIG.
- Any otherwise high risk neonate (judged by the clinician) who develops chickenpox and in whom VZIG prophylaxis was not given within 24 hours of exposure.

Herpes simplex virus (HSV) infection; therapeutic (suspected or confirmed) or pre-emptive therapy in the high-risk asymptomatic neonate

Intravenous

<table>
<thead>
<tr>
<th>Corrected Age</th>
<th>Dose (mg/kg/dose)</th>
<th>Frequency (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational Age PLUS Postnatal Age (weeks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 30 weeks</td>
<td>20mg/kg/dose</td>
<td>every 12 hours</td>
</tr>
<tr>
<td>≥ 30 weeks</td>
<td>20mg/kg/dose</td>
<td>every 8 hours</td>
</tr>
</tbody>
</table>
See below as a guide to dose adjustment in renal dysfunction for babies ≥30 weeks* corrected gestational age. Consider in conjunction with clinical picture:

<table>
<thead>
<tr>
<th>Serum Creatinine (μmol/L)</th>
<th>Dose adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>70 - 100</td>
<td>Give usual dose every 12 hours</td>
</tr>
<tr>
<td>101 - 130</td>
<td>Give usual dose every 24 hours</td>
</tr>
<tr>
<td>&gt; 130</td>
<td>Decrease dose by 50% and give every 24 hours</td>
</tr>
</tbody>
</table>

*For dose interpretation in renal impairment in babies < 30 weeks corrected gestational age, consult Neonatologist/Infectious Diseases.

Length of therapy should be guided by clinical picture, underlying pathology and specialist consultation: as a guide, the minimum treatment durations are as follows, but require consultation with Infectious Diseases:

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Minimum Treatment Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSV (encephalitis/disseminated disease)</td>
<td>21 days (IV)*</td>
</tr>
<tr>
<td>HSV (skin/eye/mouth)</td>
<td>14 days (IV)</td>
</tr>
<tr>
<td>HSV (high risk asymptomatic neonate)</td>
<td>10 days (IV)</td>
</tr>
<tr>
<td>Varicella Zoster Virus</td>
<td>seek expert advice</td>
</tr>
</tbody>
</table>

*see below for ongoing suppressive therapy

Herpes simplex virus (HSV) suppressive therapy

Oral
Suppressive therapy, for infants with HSV encephalitis
20mg/kg/dose, three times a day for 6 months after completion of IV treatment.
Oral therapy should not be recommended for therapeutic or pre-emptive treatment of HSV in the neonate

Preparation and Administration

Intravenous
Dilute 2mL of the 25mg/mL aciclovir injection with 8mL sodium chloride 0.9% (to a total volume of 10mL). Shake well to ensure thorough mixing. The resulting solution contains 5mg/mL aciclovir.

<table>
<thead>
<tr>
<th>Dose</th>
<th>10mg</th>
<th>20mg</th>
<th>30mg</th>
<th>40mg</th>
<th>50mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>2mL</td>
<td>4mL</td>
<td>6mL</td>
<td>8mL</td>
<td>10mL</td>
</tr>
</tbody>
</table>

Infuse over 1 hour
Discard remaining solution
**Oral**

The lowest strength tablet available is 200mg. It is recommended to round off the dose to the nearest quarter of a tablet and give dispersed in small amount of water (5-10mL)

**Compatible Fluids**

Glucose 5%, Glucose Sodium Chloride combinations, Sodium chloride 0.9%

**Adverse Effects**

**Common**

Vomiting, diarrhoea, encephalopathy, injection site reactions

**Infrequent**

Agitation, oedema, renal impairment, constipation, rash, transient elevation of hepatic transaminases and total bilirubin

**Rare**

Coma, seizures, leucopenia, neutropenia, thrombocytopenia, crystalluria, hepatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis

Anaphylactic shock is not commonly seen in neonates

**Monitoring**

> Periodic full blood count
> Periodic renal and liver function

**Practice Points**

> Oral aciclovir has poor oral bioavailability. Intravenous administration is the preferred route in neonates.
> Slow infusion and adequate hydration can minimise renal toxicity caused by precipitation of aciclovir in renal tubules.
> Discard the solution if visual turbidity or crystallisation occurs before or during infusion.
> Store at room temperature to prevent precipitation.
> Maternal chickenpox in the peripartum period poses a risk of severe neonatal varicella, with a mortality rate up to 30%. The timing of maternal infection in relation to delivery determines the risk to the infant.
> See the Australian Society of Infectious Diseases ‘Management of Perinatal Infections’ Guideline for further information
> If required, Varicella Zoster Immunoglobulin (VZIG) should be given to the baby as early as possible after delivery or exposure but must be within 72 hours.
References


Document Ownership & History

<table>
<thead>
<tr>
<th>Developed by:</th>
<th>SA Maternal, Neonatal &amp; Gynaecology Community of Practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact:</td>
<td><a href="mailto:Health.NeoMed@sa.gov.au">Health.NeoMed@sa.gov.au</a></td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>Commissioning and Performance, SA Health</td>
</tr>
<tr>
<td>Next review due:</td>
<td>7/12/2026</td>
</tr>
<tr>
<td>ISBN number:</td>
<td>978-1-76083-393-0</td>
</tr>
<tr>
<td>CGQS reference:</td>
<td>NMG007</td>
</tr>
<tr>
<td>Policy history:</td>
<td></td>
</tr>
<tr>
<td>Is this a new policy (V1)?</td>
<td>N</td>
</tr>
<tr>
<td>Does this policy amend or update and existing policy?</td>
<td>Y</td>
</tr>
<tr>
<td>If so, which version?</td>
<td>V3.0</td>
</tr>
<tr>
<td>Does this policy replace another policy with a different title?</td>
<td>N</td>
</tr>
<tr>
<td>If so, which policy (title)?</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/12/2021</td>
<td>V3.0</td>
<td>Domain Custodian, Clinical Governance, Safety and Quality</td>
<td>Formal review</td>
</tr>
<tr>
<td>7/3/2017</td>
<td>V2.0</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Update and review</td>
</tr>
<tr>
<td>11/2012</td>
<td>V1.0</td>
<td>SA Maternal &amp; Neonatal Clinical Network</td>
<td>Original Version</td>
</tr>
</tbody>
</table>